Previous 10 | Next 10 |
Natera Presents Latest Signatera™ MRD Data in Breast Cancer at SABCS 2021 PR Newswire AUSTIN, Texas , Dec. 9, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its latest fin...
Natera's Panorama SMART Study Results Accepted for Publication by the American Journal of Obstetrics and Gynecology (AJOG) PR Newswire AUSTIN, Texas , Nov. 19, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and ...
Medicare Publishes Final Local Coverage Determination for Pan-Cancer Immunotherapy Monitoring with Natera's Signatera™ MRD Test Expands Medicare coverage of Signatera beyond its initial indication in early-stage CRC PR Newswire AUSTIN, Texas , Nov. 11, 2...
The following slide deck was published by Natera, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Natera, Inc. 2021 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Natera Inc (NASDAQ: NTRA) Q3 2021 Earnings Call Nov 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Natera Inc (NTRA) Q3 2021 Earnings Call Transcript
Natera, Inc. (NTRA) Q3 2021 Earnings Conference Call November 4, 2021 16:30 ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager of Oncology & Transplant Conference Call Participants Tejas Savant - Mo...
Natera (NASDAQ:NTRA): Q3 GAAP EPS of -$1.63 misses by $0.34. Revenue of $158.1M (+61.2% Y/Y) beats by $6.18M. Press Release For further details see: Natera EPS misses by $0.34, beats on revenue
Natera Reports Third Quarter 2021 Financial Results PR Newswire AUSTIN, Texas , Nov. 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing, today reported financial results for the third quarter ended September...
Natera Validates Prospera™ With Quantification in Multi-Site, Prospective Trifecta Study Study represents the largest prospective, fully biopsy-matched cohort of dd-cfDNA for kidney transplant recipients PR Newswire AUSTIN, Texas , Nov. 3, 2021 /PRNews...
Natera Announces Third Quarter 2021 Earnings Conference Call PR Newswire AUSTIN, Texas , Oct. 28, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, today announced that it will release r...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...